Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical ...

Otto and co-author Sean Edgerton, a PhD student focused on genomics and infectious diseases at the University of British ...

Key findings • Sarcoidosis patients are prone to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, increased severity, morbidity and greater mortality of coronavirus disease 2019 ...

Dr Jim Hughes, of the US Centers for Disease Control, said he did not think severe acute respiratory syndrome (Sars) could be eradicated in the Far East. Sars has infected at least 2,700 people ...

The first mention of Covid-19 in the Queens Chronicle came on Jan. 30, 2020, in a story headlined “Coronavirus fears seep ...

We ended up getting lucky with SARS. The coronavirus that caused it turned out to be far less infectious than it first ...

Coronavirus and respiratory syncytial virus (RSV ... also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first record of illness linked to SARS-CoV-2 was in China ...

By Telesha Ramnarine When she started in the medical field some 12 years ago, Olivia (not her real name) couldn’t tell that a ...

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

Scientists uncover how a ‘silent’ virus ... syndrome in children (MIS-C), which is a rare but severe condition of ...